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The United Kingdom (UK) immune thrombocytopenia (ITP) forum is a working group 
of health professionals with an interest in the care of patients with ITP 
(http://itpsupport.org.uk/itpforum/about.htm).  We were aware of differences in when 
and how thrombopoietin receptor agonists (TPO-RAs) are used throughout the UK 
and a 12 question survey was designed to assess several aspects of prescribing 
practice.  In April 2015, it was circulated to all 16 paediatric and all 20 adult UK 
haematology consultants providing an ITP clinical centre service.  All responses 
were received by November 2015.  14/20 (70%) adult clinical centres responded.  
Their responses are in table 1 and relevant published evidence is reviewed in 
supplementary appendix 1.  Only 2/16 (12.5%) paediatric haematologists responded, 
probably reflecting the absence of a paediatric TPO-RA licence at that time.  
Because of the low overall response rate, and the influence of an active trial 
protocol, these two are not included.  
 
We found that most respondents positioned TPO-RAs ahead of splenectomy, but 
usually after at least one alternative second line agent.  Many cited that individual 
patient factors (including preference) or local funding arrangements influenced this 
decision.  Current National Institute for Health and Care Excellence (NICE) 
recommendations are for TPO-RA use in a) patients with refractory chronic ITP post-
splenectomy or b) when splenectomy is contra-indicated, in those refractory to 
standard and rescue therapies or with severe disease needing frequent rescue 
therapies.  This position reflected the European Medicines Agency (EMA) marketing 
authorisation for TPO-RA at the time.  However TPO-RAs remain the only licensed, 
best studied and most efficacious second line medical therapy and the EMA 
authorization was revised in December 2015 to “adult chronic immune (idiopathic) 
ITP patients who are refractory to other treatments (e.g. corticosteroids, 
immunoglobulins)” and for eltrombopag in January 2016 to “patients age 1 year and 
above who are refractory to other treatments e.g. corticosteroids, immunoglobulins”. 
 
Some clinicians started romiplostim at 2-3 µg/kg rather than the 1 µg/kg 
recommended in the summary of product characteristics (SPC) (Amgen Ltd, 2016), 
or increased the dose at greater than the recommended 1 µg/kg per week under 
some circumstances.  The average effective dose in most studies was 4-5 µg/kg and 
higher starting doses or faster titration, depending on clinical urgency, has been 
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used in clinical trials (Kuter et al, 2008;Kuter et al, 2010) and supported by expert 
opinion (Mitchell & Bussel, 2015). 
 
The efficacy and side effect profiles of romiplostim and eltrombopag are sufficiently 
similar that most respondents offered patients the choice between a daily tablet with 
dietary restrictions and a weekly injection.  Respondents were divided on whether to 
routinely carry out a bone marrow biopsy prior to starting TPO-RA but all would do 
so to exclude myelodysplasia if any diagnostic uncertainty existed.  Clinicians did not 
consider biopsy during treatment unless there were changes on the full blood count 
(FBC) or film suggesting fibrosis.  Marrow fibrosis occurs in a subset of patients on 
TPO-RA.  This resolves on stopping TPO-RA in the majority of cases (Kuter et al, 
2009).  So far, this fibrosis has not appeared to result in adverse clinical outcomes 
but this remains a potential concern, particularly if collagen fibrosis proves to 
increase with treatment duration (Ghanima et al, 2014) and this will only be 
established through longer follow up. 
 
All respondents waited no more than 3-6 weeks at maximum dose of TPO-RA before 
determining a treatment failure.  All conducted laboratory monitoring with FBC/film, 
and liver function tests in patients on eltrombopag.  Monitoring was initially weekly 
but some respondents extended the interval up to 8 weeks in stable patients.   
 
In patients on TPO-RA, the SPCs recommend dose interruption when platelets are 
>250 x 109/l.  However for approximately 10% of patients, dose interruption results in 
rebound below the pre-treatment baseline within days (Cuker, 2010) and frequent 
dose changes can lead to wide platelet count fluctuations.  Respondents would 
initially manage wide fluctuations with small and infrequent dose changes.  Some 
would switch from romiplostim to eltrombopag if wide swings persisted.   
 
Respondents would also consider switching either TPO-RA to the other after 
treatment failure.  This strategy proved effective in 44-80% of patients in one study, 
despite the first TPO-RA having been titrated to maximum dose (Khellaf et al, 2013). 
In patients refractory to TPO-RAs, 12/14 respondents would consider adding an 
agent such as mycophenolate, low dose steroid or intravenous immunoglobulins.  
Combining treatments with different mechanisms of action appears to be beneficial 
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in refractory patients. TPO-RA combined with immunosuppression was effective in 
7/10 severe chronic ITP patients who had not responded to rituximab, splenectomy, 
romiplostim and eltrombopag (Mahevas et al, 2016). 
 
An unexpected finding has been that up to a third of patients responding to TPO-RA 
can be weaned off treatment and still maintain their response (Newland et al, 2016). 
All respondents would taper TPO-RA after a period with stable normal platelet 
counts. 
 
Based on available evidence, we draw the following conclusions:  
 Although decisions must still be individualised, TPO-RAs should be considered in 
patients who have failed first line therapy. 
 For romiplostim, both the starting dose and speed of titration can be higher than 
is recommended in the SPC and this should be based on the patient’s clinical 
circumstances. 
 The choice of TPO-RA can usually be patient led, based on preferred route of 
administration. 
 Bone marrow biopsy should be considered prior to TPO-RAs where diagnostic 
uncertainty exists.  Biopsy is also required during treatment where FBC/film 
changes suggest fibrosis.  Clinicians should also be vigilant for emerging data on 
fibrosis risk in patients receiving long term TPO-RAs. 
 In patients with wide platelet fluctuation on romiplostim, make small and 
infrequent dose changes.  If control remains poor, switching to eltrombopag can 
be effective. 
 In patients failing to respond to the maximum dose of either TPO-RA, switching 
TPO-RA is a reasonable option but treatment decisions should be individualised.   
 In patients refractory to TPO-RAs, adding an immunosuppressant such as 
mycophenolate to TPO-RA may also be useful.   
 In patients with a stable platelet count of 50-150 x 109/l on TPO-RA, a taper 
should be considered periodically to ensure that remission is not missed. 
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Question Responses 
1) When would you 
start TPO-RAs? 
In addition to NICE indications, all 14 respondents would consider TPO-RAs 
before splenectomy in some situations.  The majority (8/14) would use TPO-
RAs after failure of one steroid sparing agent (mycophenolate or rituximab).  
Two after failure of two steroid sparing agents (oral immunosuppression 
then rituximab).  Three presented TPO-RAs as a second line option to 
patients (vs. mycophenolate, rituximab or splenectomy).  One respondent 
would follow NICE guidance but consider second line use in bleeding 
patients failing steroids and intravenous immunoglobulins. 
 
2) What starting dose 
of TPO-RA would 
you use? 
All respondents would use eltrombopag as recommended in the SPC.  One 
exclusively used eltrombopag because of wide platelet count fluctuation with 
romiplostim.  Three started romiplostim at 1 μg/kg, three more started at 1 
μg/kg but 3 μg/kg in bleeding patients or if steroid refractory.  One started at 
2 μg/kg and two more at 2-3 μg/kg, usually rounding to the nearest vial 
size*.  Two started at 250 μg and two at 3 μg/kg.  Reasons provided for 
starting at 1 μg/kg were compliance with SPC guidance and experience that 
some patients required ≤1 μg/kg maintenance.  Those starting at 2-3 μg/kg 
or 250 μg cited cost effectiveness and achieving therapeutic platelet counts 
faster.  One respondent had changed practice when local audit showed only 
1 in 20 patients responded to a starting dose of 1 μg/kg.  Two reported 
increasing at >1 μg/kg per week in symptomatic unresponsive patients. 
 
3) On what do you 
base the choice of 
TPO-RA? 
Of the 13 clinicians who used both drugs, all would offer the patient a 
choice.  Two commented that they found eltrombopag easiest for short term 
treatment e.g. for surgery, since fewer dose adjustments are required. 
 
4) How long do you 
wait for a TPO-RA 
response? 
When determining the effectiveness of treatment, all clinicians would wait for 
no more than 3-6 weeks at the maximum dose of TPO-RA.  Within that 
range, duration was usually shorter when no reduction in haemorrhagic 
symptoms was observed. 
 
5 & 6) Do you 
perform a bone 
marrow prior to 
starting TPO-RA and 
at regular intervals 
during treatment? 
Seven respondents did and seven usually did not carry out a pre-treatment 
bone marrow biopsy. However all qualified this by stating that biopsy was 
more likely to be done if there was any diagnostic uncertainty.  No clinician 
carried out regular biopsies during treatment.  Instead, the FBC/film was 
monitored and biopsy taken if there were changes suggestive of fibrosis. 
 
7) How do you 
manage wide 
fluctuations in 
platelet counts? 
There was consensus that the first step was to make smaller and less 
frequent dose changes.  This was achieved through less frequent FBC 
checks in asymptomatic patients or reacting to out of range counts only if 
persistent on several occasions.  Five cited bleeding symptoms as an 
indication to increase dose and one would interrupt therapy if the platelet 
count was above the normal range, especially in those with risk factors for 
cardiovascular disease.  One respondent would manage wide fluctuation by 
reducing TPO-RA dose and introducing a second agent.  Three reported 
that they would switch to eltrombopag if wide swings were persistent and 
one only used eltrombopag for this reason. 
 
8) Would you add in 
a second agent to 
facilitate responses? 
Ten would consider adding mycophenolate, eight would consider a low dose 
of steroid and one IVIg.  Two respondents had no experience of adding a 
second agent to TPO-RAs. 
 
9) How often do you 
monitor the patient? 
All respondents started monitoring weekly.  However for stable patients, the 
maximum interval between reviews varied.  Six monitored monthly, three 4-
6 weekly and five 8 weekly. 
 
10) What blood tests 
are done during 
All would monitor with blood films and LFTs (two only monitored LFTs with 
eltrombopag). Seven also monitored renal function. 
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follow up in addition 
to the FBC? 
11) Is there any role 
for switching 
between the two 
TPO-RA? 
All thirteen respondents using both TPO-RAs, would consider switching 
agents.  Respondents switched for lack of response, wide platelet 
fluctuation or other adverse events.  Two commented that they switched 
when next TPO-RA dose was due, to avoid treatment overlap. 
 
12) Do you ever 
discontinue TPO-
RA? 
All respondents would discontinue TPO-RA for adverse effects or lack of 
response.  Respondents would also taper down TPO-RA in patients with 
stable platelet counts in order to assess for a possible remission.  Of those 
defining a platelet threshold, three would taper drug for a stable platelet 
count in the normal range, two for stable platelets >100 x 109/l and one 
tapered to the minimum dose required to keep platelets >50 x 109/l.  Two 
specified they would consider a taper in stable patients after one year. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Thrombopoietin receptor antagonist questionnaire  
TPO-RA; thrombopoietin receptor agonist, NICE; national institute for health and care 
excellence, SPC; summary of product characteristics, FBC; full blood count, LFTs; liver 
function tests, IVIg; intravenous immunoglobulins. 
*smallest vial is 250 µg 
